VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update
VolitionRx (NYSE AMERICAN: VNRX) has announced a conference call scheduled for Friday, November 15 at 8:30 a.m. U.S. Eastern Time to discuss their third quarter 2024 financial and operating results, along with a business update. The call will be hosted by key executives including Louise Batchelor, Cameron Reynolds, Terig Hughes, Dr. Tom Butera, and Dr. Andrew Retter. A live audio webcast will be available, and a telephone replay will be accessible until November 29, 2024.
VolitionRx (NYSE AMERICAN: VNRX) ha annunciato una conferenza telefonica programmata per venerdì 15 novembre alle 8:30 a.m. ora orientale degli Stati Uniti per discutere i risultati finanziari e operativi del terzo trimestre 2024, insieme a un aggiornamento aziendale. La chiamata sarà ospitata da importanti dirigenti tra cui Louise Batchelor, Cameron Reynolds, Terig Hughes, Dr. Tom Butera e Dr. Andrew Retter. Sarà disponibile una trasmissione audio in diretta, e una registrazione telefonica sarà accessibile fino al 29 novembre 2024.
VolitionRx (NYSE AMERICAN: VNRX) ha anunciado una conferencia telefónica programada para el viernes 15 de noviembre a las 8:30 a.m. hora del Este de EE.UU. para discutir sus resultados financieros y operativos del tercer trimestre de 2024, junto con una actualización sobre el negocio. La llamada será conducida por ejecutivos clave, incluyendo a Louise Batchelor, Cameron Reynolds, Terig Hughes, Dr. Tom Butera y Dr. Andrew Retter. Habrá una transmisión de audio en vivo disponible, y una grabación telefónica estará accesible hasta el 29 de noviembre de 2024.
VolitionRx (NYSE AMERICAN: VNRX)는 2024년 11월 15일 금요일 오전 8시 30분(미국 동부 표준시)에 예정된 전화 회의를 발표하며, 2024년 3분기 재무 및 운영 결과에 대해 논의하고 비즈니스 업데이트도 진행할 예정입니다. 이 회의는 Louise Batchelor, Cameron Reynolds, Terig Hughes, Dr. Tom Butera 및 Dr. Andrew Retter를 포함한 주요 경영진이 주최합니다. 실시간 오디오 웹캐스트가 제공되며, 전화 녹음은 2024년 11월 29일까지 접근할 수 있습니다.
VolitionRx (NYSE AMERICAN: VNRX) a annoncé une conférence téléphonique prévue pour vendredi 15 novembre à 8h30, heure de l'Est des États-Unis, afin de discuter de ses résultats financiers et opérationnels du troisième trimestre 2024, ainsi que d'une mise à jour sur l'entreprise. L'appel sera animé par des cadres clés, notamment Louise Batchelor, Cameron Reynolds, Terig Hughes, Dr. Tom Butera et Dr. Andrew Retter. Un webcast audio en direct sera disponible et un enregistrement téléphonique sera accessible jusqu'au 29 novembre 2024.
VolitionRx (NYSE AMERICAN: VNRX) hat eine Telefonkonferenz für Freitag, den 15. November um 8:30 Uhr US-Ostküstenzeit angekündigt, um über die finanziellen und operativen Ergebnisse des dritten Quartals 2024 sowie ein Geschäftsupdate zu sprechen. Die Konferenz wird von wichtigen Führungskräften wie Louise Batchelor, Cameron Reynolds, Terig Hughes, Dr. Tom Butera und Dr. Andrew Retter geleitet. Eine Live-Audioübertragung wird zur Verfügung stehen, und eine Telefonwiedergabe wird bis zum 29. November 2024 zugänglich sein.
- None.
- None.
Conference call to take place on Friday, November 15 at 8:30 a.m. U.S Eastern Time
Event: VolitionRx Limited Third Quarter 2024 Earnings and Business Update Conference Call
Date: Friday, November 15, 2024
Time: 8:30 a.m.
Toll/International: 1-201-493-6779
Conference ID: 13750104
Louise Batchelor, Group Chief Marketing & Communications Officer will host the call along with Cameron Reynolds, President and Group Chief Executive Officer of Volition, Terig Hughes, Group Chief Financial Officer, Dr Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC and Dr. Andrew Retter, Chief Medical Officer. The call will provide an update on important events that have taken place in the third quarter of 2024 and upcoming milestones.
A live audio webcast of the conference call will also be available on this link. In addition, a telephone replay of the call will be available until November 29, 2024. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor/Debra Daglish,
Volition,
mediarelations@volition.com,
+44 (0)7557 774620
View original content:https://www.prnewswire.com/news-releases/volitionrx-limited-schedules-third-quarter-2024-earnings-conference-call-and-business-update-302299871.html
SOURCE VolitionRx Limited
FAQ
When is VolitionRx (VNRX) Q3 2024 earnings call scheduled?
How can I access VolitionRx (VNRX) Q3 2024 earnings call?